Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity

Allergy and Asthma Proceedings

Volumn 32, Issue 1, 2011, Pages 36-42

  Bernstein, Jonathan A ^a   Ritchie, Bruce ^b   Levy, Robyn J ^c   Wasserman, Richard L ^d   Bewtra, Againdra K ^e   Hurewitz, David S ^f   Obtułowicz, Krystyna ^g   Reshef, Avner ^h   Moldovan, Dumitru ⁱ   Shirov, Todor ^j   Grivcheva Panovska, Vesna ^k   Kiessling, Peter C ^l   Keinecke, Heinz Otto ^m   Craig, Timothy J ⁿ  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Family Allergy and Asthma Center   (United States)

^d Pediatric Allergy/Immunology Associates   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Allergy Clinic of Tulsa Inc   (United States)

^g JAGIELLONIAN UNIVERSITY   (Poland)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^k PHI University Clinical Center   (Macedonia)

^l CSL BEHRING GMBH   (Germany)

^m ACCOVION GMBH   (Germany)

ⁿ PENN STATE COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; PLACEBO;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ARTICLE; DIARRHEA; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PAIN ASSESSMENT; SYMPTOMATOLOGY; TREATMENT OUTCOME; VALIDATION PROCESS; VOMITING;

ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIER ESTIMATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79551490988     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3404     Document Type: Article

References (17)

1. Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: Pharmacology, safety, efficacy and future directions. Expert Rev Clin Immunol 4:13-20, 2008.
2. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends Mol Med 15:69-78, 2009.
3. Dewald G, and Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343:1286-1289, 2006.
4. Zuraw BL, and Christiansen SC. Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc 30:487-492, 2009.
5. Agostoni A, and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206-215, 1992.
6. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 100(suppl 2):S30-S40, 2008.
7. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 139:379-394, 2005.
8. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 114:629-637, 2004.
9. Christiansen SC, and Zuraw BL. Update on therapeutic developments for hereditary angioedema. Allergy Asthma Proc 30:500-505, 2009.
10. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1-esterase inhibitor (C1-INH) concentrate compared to placebo in patients with acute abdominal or facial HAE attacks. J Allergy Clin Immunol 124:801-808, 2009.
11. Vernon MK, Rentz AM, Wyrwich KW, et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 18:929-939, 2009.
12. Waytes AT, Rosen FS, and Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 334:1630-1634, 1996.
13. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38:540-549, 1998. (Pubitemid 28317229)
14. Frank MM. Hereditary angioedema: A current state-of-the-art review, VI: Novel therapies for hereditary angioedema. Ann Allergy Asthma Immunol 100(suppl 2):S23-S29, 2008.
15. Blood Products Advisory Committee. Briefing document for Cinryze. Available online at www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4355B2-2.pdf; last accessed September 2010.
16. European Medicines Agency. Report for Firazyr. Available online at www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/ human/000899/WC500022968.pdf; last accessed September 2010.
17. Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120:416-422, 2007. (Pubitemid 47102386)